← All trials
NCT03634488
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 18, 2021
- Primary completion
- Oct 5, 2022
- Completion date
- Nov 30, 2023
- First posted
- Aug 16, 2018
- Last posted
- Oct 6, 2023
- Enrollment
- 110
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vanderbilt UniversityLead sponsor
- Aminu Kano Teaching HospitalCollaborator
- Vanderbilt UniversityOverall official - principal investigator
- Vanderbilt UniversityReponsible party - principal investigator
- Vanderbilt UniversitySponsor investigator
- Vanderbilt UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.